April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Sumoylation of the 32 kD Pax-6 Activates Its Transcriptional Activity
Author Affiliations & Notes
  • L. Gong
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • Q. Yan
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • D. Yuan
    College of Life Science, Hunan Normal University, Changsha, China
  • L. Zhang
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • J.-P. Liu
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • M. Deng
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • S. Sun
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • H. Ma
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
  • D. W. Li
    Biochem & Molecular Biol, Univ of Nebrask Medical Center, Omaha, Nebraska
    Department of Ophthalmology & Visual Sciences, University of Nebraska Medical Center, Omaha, Nebraska
  • Footnotes
    Commercial Relationships  L. Gong, None; Q. Yan, None; D. Yuan, None; L. Zhang, None; J.-P. Liu, None; M. Deng, None; S. Sun, None; H. Ma, None; D.W. Li, None.
  • Footnotes
    Support  NIH Grant EY15765 and EY18380
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2614. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Gong, Q. Yan, D. Yuan, L. Zhang, J.-P. Liu, M. Deng, S. Sun, H. Ma, D. W. Li; Sumoylation of the 32 kD Pax-6 Activates Its Transcriptional Activity. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2614.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Pax-6 is a master regulator controlling eye and brain development. Four isoforms of Pax-6, p46, p48, p43 and p32/33, have been detected in the vertebrate eye. Absence of the paired domain in the 32-kD Pax-6 distinguishes it from the other three forms. How is the 32-kD Pax-6 acting as a transcription factor remains unknown. In the present study, we demonstrated that activation of the 32-kD Pax-6 requires sumoylation, an important posttranslational modification.

Methods: : Western-blot analysis was used to detect the nuclear and cytoplasmic distributions of Pax-6 in human lens epithelial cell line (FHL-124). Gel mobility shifting assays were used to test the binding activities of different forms of Pax-6 to a P3 sequence specific for homeodomain. In vitro sumoylation assay was conducted to detect sumoylation of 32-kD Pax-6. Immunohistochemistry and co-immunoprecipitation were used to detect the in vivo interactions between Pax-6 and sumo proteins.

Results: : Three Pax-6 isoforms (46-, 43- and 32-kD) were detected in the nuclear extracts but only one isoform (43-kD) was found in the cytoplasm. Only the 43-kD Pax-6 displayed binding ability to the P3 sequence. The 32- and 46-kD Pax-6 synthesized in vitro lack the binding ability to P3 sequence. After incubating with the Pax-6-depeleted nuclear extract, the 32-kD but not the 46-kD Pax-6 exhibited strong binding ability to P3 sequence. This binding activity of 32-kD Pax-6 was prevented when the nuclear extract was pre-cleared with sumo antibodies. The interacting complexes of Pax-6 and sumo proteins were detected in developing mouse eye.

Conclusions: : The 32-kD and 46-kD Pax-6 display differential DNA binding activities to the P3 sequence and likely regulate different downstream target genes. Moreover, sumoylation of the 32-kD Pax-6 is necessary to activate its transcriptional activity.

Keywords: cataract • transcription factors • gene/expression 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×